Trial Profile
A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Lixivaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; Pharmacokinetics
- Acronyms ELISA
- Sponsors Palladio Biosciences
- 18 Feb 2020 Status changed from active, no longer recruiting to completed.
- 14 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2019 According to Palladio Biosciences media release, data from this study will be presented at the American Society of Nephrologys Kidney Week 2019, to be held in Washington, D.C. on November 7-10.